News Archives - Page 80 of 87

TuesdayJul 26, 2022 12:12 pm

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Scheduled Annual Shareholder Meeting

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled its annual shareholder meeting. The company’s 2022 Annual Meeting of Shareholders will begin at 10 a.m. ET on Aug. 15, 2022; the meeting will be held virtually. According to the announcement, notice of the annual meeting and a proxy statement containing meeting details should be available approximately July 25, 2022; individuals who were shareholders of record at close of business on July 11, 2022, will have access to the information. The company noted that meeting materials will be mailed to shareholders, and the information…

TuesdayJul 26, 2022 10:24 am

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Announces Samsung Mexico SDS Contract Award

Freight Technologies (NASDAQ: FRGT), a technology company developing solutions to optimize and automate the supply chain process as well as providing a platform for B2B cross-border shipping in the NAFTA region, has been awarded a contract with Samsung Mexico in regard to its SDS business. According to the announcement, FRGT has already started to use its platform to assist with shipments from Mexico to the United States. Fr8App delivers cross-border capacity “during a difficult market when others have not been able to do so,” said a Samsung Mexico official, who noted that the company has more than 100 trucks going from…

MondayJul 25, 2022 11:53 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on Phase 2 EB Trial

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”). Based on safety data of the first five adult patients who completed the phase 2 study, an independent data monitoring committee agreed it is safe to allow the enrollment of adolescent patients, defined as persons aged twelve to seventeen with EB. “We are pleased that the initial safety data from InMed’s phase 2 EB clinical trial has allowed…

FridayJul 22, 2022 11:59 am

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) and Colombian Senator Fighting to Legalize Recreational Cannabis Meet

Flora Growth’s (NASDAQ: FLGC) CEO Luis Merchan recently met with Senator Gustavo Bolivar, a Colombian representative who introduced a bill that creates the framework for recreational cannabis in the state. The bill was introduced on July 20, 2022, the same day that Merchan and Bolivar met. The two gentlemen met before Bolivar, a key author of the bill, introduced the bill to Congress. The two talked about what the bill might mean to cannabis countries operating in the country as well as for Colombia’s growing domestic and international cannabis markets, including both domestic trade and international exports. According to the…

ThursdayJul 21, 2022 2:34 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Issues Reminder for Upcoming Annual Shareholder Meeting

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today issued a reminder for its current shareholders regarding the upcoming annual shareholder meeting. Beginning at 9:30 a.m. ET on July 26, 2022, Mullen will conduct a required formal shareholder meeting, which will be followed by a company presentation by David Michery, CEO and chairman of Mullen Automotive. The in-person meeting will be held at the NASDAQ Building, 151 West 42nd Street, 10th Floor (West Cafe – Market Site Event Space), New York, NY 10036. Please note that NASDAQ requires registration (see instructions in press release) for all those planning…

WednesdayJul 20, 2022 12:59 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Enters Strategic Partnership for Production of Vista(R)-X90 Lidar

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, today announced that it has selected Fabrinet (NYSE: FN), a leading provider of advanced precision optical and electronic manufacturing services, for the production of its Vista(R)-X90 lidar, which will be deployed in the industry’s largest ADAS lidar series production program. According to the update, Cepton selected Fabrinet for its deep expertise in advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services for the production of high-performance, proprietary assemblies of its Vista-X90 lidars. “At Cepton, our goal is to be the world’s go-to supplier of…

MondayJul 18, 2022 10:41 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Michael Woudenberg as Chief Operating Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced its appointment of Michael Woudenberg as chief operating officer of the company, overseeing all day-to-day operations. Woudenberg previously served as senior vice president of chemistry, manufacturing and controls. For the past several years, he has been an integral part of InMed’s executive team, supporting multiple functions within the organization. Prior to joining InMed, Woudenberg had over 20 years of successful drug development, process engineering, GMP manufacturing and general management experience at all levels of various companies. “I would like to congratulate Mike…

ThursdayJul 14, 2022 1:05 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awarded Patent in Japan, Submits Briefing Book

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, announced that it has been notified that it will be awarded a new patent in Japan, which makes the 26th world patent for the company. The patent, which is the third one granted in Japan, recognizes the company’s patented drug-delivery technology, DehydraTECH(TM), and its ability to deliver active pharmaceutical ingredients (“APIs”) more efficiently, regardless of the “food effect,” or the presence of food in the gastrointestinal system. Drug delivery is a key component of reliable drug dosing. According to the announcement, this is the first patent issued from Lexaria’s seventh…

WednesdayJul 13, 2022 4:08 pm

TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) Expands IP Estate with Receipt of Third US Patent for CycloSam(R)

QSAM Biosciences (OTCQB: QSAM) is a company developing next-generation targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of cancer and related diseases. The company today announced that the United States Patent & Trademark Office has granted a key patent protecting how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in an efficient, facile and reproducible process at lower costs. “This patent issuance marks our third granted patent in the United States and further strengthens our IP estate, consisting of 14…

WednesdayJul 13, 2022 2:38 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Nearing Start Date for Its Human Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the pending start of its upcoming human nicotine study NIC-H22-1. Through the study, Lexaria expects to evidence that processing purified nicotine with its patented drug delivery technology, DehydraTECH(TM), leads to enhanced oral-tissue absorption and reduced negative experiences. NIC-H22-1, a minimum 36-person human pharmacokinetic (“PK”) randomized, double blinded, cross-over study, will compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. The primary objective of the study is data collection from blood samples that will evidence…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Breaks Categories: News